BioLineRx Ltd. (NASDAQ:BLRX) announced on November 18, 2026, that it has entered into an agreement to sell its 14.4% royalty interest in future net sales of APHEXDA (motixafortide) to Soleus Capital Management, L.P. and its affiliates for a one-time payment of $5.6 million.

Key Highlights

  • One-time payment: BioLineRx will receive $5.6 million from Soleus Capital in exchange for its 14.4% royalty interest in future APHEXDA net sales.
  • Retained interests: BioLineRx retains rights to potential commercial milestone payments under the Ayrmid agreement, as well as royalties attributable to periods prior to closing.
  • Excluded royalty slice: A separate 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx is not part of the transaction and remains with that party.
  • Proceeds use: Funds are intended for GLIX1 clinical development, working capital, general corporate purposes, and a partial loan repayment to BlackRock EMEA Venture and Growth Lending.
  • Minimum cash requirement eliminated: Following the partial loan repayment, the company's minimum cash balance requirement under the loan agreement, currently $4 million, will be eliminated.
  • GLIX1 trial enrollment: The Phase 1/2a clinical trial of GLIX1 is currently enrolling the fourth of five planned dosing cohorts.
  • Expected closing: The transaction is expected to close on or about November 30, 2026.

BioLineRx Monetizes APHEXDA Royalty Stream in Non-Dilutive Financing Deal

According to the filing, BioLineRx entered into an agreement under which Soleus Capital Management, L.P. and its affiliates will acquire the company's 14.4% royalty interest in future net sales of APHEXDA under BioLineRx's existing license agreement with Ayrmid Pharma Ltd. The company described the transaction as non-dilutive. The 3.6% royalty interest attributable to the original licensor of motixafortide to BioLineRx is excluded from the deal and will, according to the filing, "continue to retain its interest in the royalty stream."

The filing states that BioLineRx intends to use the $5.6 million proceeds to support clinical development of GLIX1, its lead development asset, as well as for working capital and general corporate purposes. The company also disclosed a partial loan repayment to BlackRock EMEA Venture and Growth Lending. The filing states that, in connection with that repayment, the minimum cash balance requirement of $4 million currently in place under the loan agreement will be eliminated.

Philip Serlin, Chief Executive Officer of BioLineRx, was quoted in the filing as saying the transaction "enables us to immediately unlock the value of our APHEXDA royalty stream and strengthen our financial position while retaining the potential for future commercial milestone payments." The filing notes that BioLineRx's Phase 1/2a clinical trial of GLIX1 in glioblastoma and other solid tumors is ongoing and currently enrolling the fourth of five planned dosing cohorts. The transaction is expected to close on or about November 30, 2026. The filing contains forward-looking statements that are subject to the company's cautionary language regarding risks and uncertainties.

What Was Disclosed

BioLineRx disclosed the sale of its 14.4% APHEXDA royalty interest to Soleus Capital for $5.6 million, retaining commercial milestone rights and pre-closing royalties. Proceeds will fund GLIX1 development, working capital, and a partial repayment of its BlackRock EMEA loan, eliminating a $4 million minimum cash requirement.